Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Post-Trial Drug Access

Drugs

Locations

Clinical Specialty

821-840 of 847 trials

Hidradenitis Suppurativa: Sonelokimab Study

We are studying the long-term safety and effectiveness of sonelokimab for people with moderate to severe hidradenitis suppurativa. This research aims to improve symptoms and quality of life for participants.

Hidradenitis Suppurativa>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementDermatology

Advanced Breast Cancer: PF-07248144 with Fulvestrant

We are studying a new treatment combining PF-07248144 and fulvestrant for adults with hormone receptor-positive, HER2-negative advanced breast cancer. This trial aims to see if it helps patients whose cancer has progressed after prior therapy.

Hormone Receptor-Positive, HER2-Negative Breast CancerConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteOncology

Breast Cancer: Patritumab Deruxtecan vs. Standard Treatment

We are studying a new medication for patients with hormone receptor-positive, HER2-negative advanced breast cancer. The goal is to see if it works better than the current treatment options.

Hormone Receptor Positive Breast Cancer>2 yearsConfirmation phase (III)Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteGynecology and ObstetricsOncology

HIV-1 Prevention: MK-8527 Oral Medication

We are studying a new once-monthly pill, MK-8527, to see if it can effectively prevent HIV-1 infection compared to a daily treatment. The trial will also assess how safe and tolerable this new medication is for participants.

HIV-1>2 yearsConfirmation phase (III)>20 visits Post-Trial Drug Access Investigational Medicines Partially RemoteInfectious DiseasesInternal Medicine

Alzheimer's Disease: KarXT + KarX-EC Treatment

We are studying a new combination treatment for agitation in people with Alzheimer's disease. The goal is to see if it can reduce agitation symptoms better than a placebo.

Alzheimer's Disease Agitation3-6 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteNeurologyPsychiatry

GSK5764227 for Advanced Gastrointestinal Tumors

We are studying a new treatment for patients with advanced unresectable or metastatic gastrointestinal tumors that have been previously treated. The trial aims to evaluate how well this treatment works and its safety.

Gastrointestinal Neoplasms6-12 monthsSafety phase (I)Efficacy phase (II)6-10 visits Post-Trial Drug Access No Placebo Cost Reimbursement Partially RemoteGastroenterologyOncology

Ulcerative Colitis: SAR441566 Study

We are investigating the effects of SAR441566 in adults with moderate-to-severe ulcerative colitis. The study aims to see if different doses can help achieve remission and improve overall health.

Ulcerative Colitis1-2 yearsEfficacy phase (II)16-20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteGastroenterologyInternal Medicine

Primary Aldosteronism: Baxdrostat Study

We are investigating how safe and effective baxdrostat is for adults with primary aldosteronism. The goal is to see if it can improve blood pressure and other health measures compared to a placebo.

Primary Hyperaldosteronism1-2 yearsConfirmation phase (III)≤5 visits Post-Trial Drug Access Investigational Medicines Partially RemoteCardiologyEndocrinologyInternal Medicine

Advanced Colorectal Cancer: OMTX705 Combination Therapy

We are studying a new drug, OMTX705, combined with regorafenib and tislelizumab for patients with advanced colorectal cancer. The goal is to evaluate its safety and effectiveness in those who have not responded to previous treatments.

Metastatic Colorectal Cancer1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access No Placebo Investigational MedicinesOncology

Alzheimer’s Disease: KarXT + KarX-EC Treatment

We are studying a new treatment for cognitive impairment in people with mild to moderate Alzheimer’s disease. The trial will check if it helps improve thinking skills and daily activities, while also ensuring safety.

Mild to Moderate Alzheimer's Disease1-2 yearsConfirmation phase (III)≤5 visits Post-Trial Drug Access Investigational MedicinesNeurologyPsychiatry

Idiopathic Hypersomnia: ALKS 2680 Study

We are evaluating a new medication, ALKS 2680, for individuals with Idiopathic Hypersomnia to see if it helps reduce excessive daytime sleepiness and is safe to use.

Idiopathic Hypersomnia3-6 monthsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteInternal MedicineNeurology

Congenital Pseudarthrosis of the Tibia: NVD003 Treatment Study

We are evaluating how effective and safe NVD003 is for children undergoing surgery for congenital pseudarthrosis of the tibia. The study will also look at its impact on bone healing and quality of life.

Congenital Pseudarthrosis>2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOrthopedics and TraumatologyPediatrics

Darolutamide and Bipolar Androgen Therapy for Advanced Prostate Cancer

We are studying whether combining Darolutamide with bipolar androgen therapy improves survival and quality of life for men with metastatic castration-resistant prostate cancer compared to standard treatments.

Metastatic Castration-Resistant Prostate Cancer>2 yearsEfficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteOncologyUrology

Tulisokibart for Ankylosing Spondylitis

We are studying a new medication, tulisokibart, to see if it helps people with ankylosing spondylitis feel better compared to a placebo. The trial will assess improvements in pain, function, and overall quality of life.

Ankylosing Spondylitis>2 yearsEfficacy phase (II)11-15 visits Post-Trial Drug Access Investigational MedicinesRheumatology

Ovarian Cancer: COM701 Treatment Study

We are testing the safety and effectiveness of COM701 for patients with relapsed platinum-sensitive ovarian cancer. The study aims to see if it can help patients maintain their health without cancer progression.

Ovarian CancerRecurrent Ovarian Cancer1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug Access Investigational Medicines Partially RemoteGynecology and ObstetricsOncology

Non-Small Cell Lung Cancer: RMC-9805 and RMC-6236 Study

We are studying a new treatment combination for patients with RAS G12D-mutant non-small cell lung cancer. The trial will evaluate the safety and effectiveness of these drugs alongside other anticancer therapies.

Non-small Cell Lung Cancer3-6 monthsEfficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Cost ReimbursementOncologyPulmonology

Mantle Cell Lymphoma: Acalabrutinib with R-CHOP

We are studying the combination of acalabrutinib and R-CHOP for patients with previously untreated mantle cell lymphoma. The goal is to see if this combination improves treatment response and is safe.

Mantle Cell Lymphoma>2 yearsEfficacy phase (II)16-20 visits Post-Trial Drug Access No Placebo Standard MedicinesHematologyOncology

Acromegaly: ALXN2420 Treatment Study

We are studying whether the new drug ALXN2420 can help lower hormone levels and improve symptoms in adults with acromegaly when used with standard treatments. This trial compares ALXN2420 to a placebo to assess its effectiveness.

Acromegaly1-2 yearsEfficacy phase (II)≤5 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteEndocrinology

Leriglitazone: Drug Interaction Study

We are studying how the new drug leriglitazone interacts with other medications and food in healthy men. This research may help us understand its safety and effectiveness when taken with certain drugs or after a high-fat meal.

AdrenoleukodystrophySafety phase (I)Post-Trial Drug Access No Placebo Investigational MedicinesInternal MedicineNeurology

IgA Nephropathy: Atacicept Treatment Study

We are testing a new medication, atacicept, to see if it helps patients with IgA nephropathy by reducing a specific protein in the blood. We will also monitor its safety and how it affects other immune factors.

IgA Nephropathy (Berger's Disease)1-2 yearsEfficacy phase (II)Post-Trial Drug Access No Placebo Investigational MedicinesNephrology

Search Clinical Trials in the European Union